<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SALAGEN- pilocarpine hydrochloride tablet, film coated </strong><br>Eisai Inc.<br></p></div>
<h1>
SALAGEN®<br>Tablets<br>(pilocarpine hydrochloride)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">SALAGEN® Tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in most non-polar solvents. Pilocarpine hydrochloride, with a chemical name of (3<span class="Italics">S</span>-<span class="Italics">cis</span>)-2(3<span class="Italics">H</span>)-Furanone, 3-ethyl-dihydro-4-[(1-methyl-1<span class="Italics">H</span>-imidazol-5-yl)methyl] mono-hydrochloride, has a molecular weight of 244.72.  </p>
<div class="Figure"><img alt="
salagen-structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb4810ec-d26f-429d-b87c-5898a7870169&amp;name=salagen-structure.jpg"></div>
<p>Each 5 mg SALAGEN® Tablet for oral administration contains 5 mg of pilocarpine hydrochloride. Inactive ingredients in the tablet, the tablet's film coating, and polishing are: carnauba wax, hypromellose, microcrystalline cellulose, stearic acid, titanium dioxide and other ingredients.</p>
<p>Each 7.5 mg SALAGEN® Tablet for oral administration contains 7.5 mg of pilocarpine hydrochloride. Inactive ingredients in the tablet, the tablet's film coating, and polishing are: carnauba wax, hypromellose, microcrystalline cellulose, stearic acid, titanium dioxide, FD&amp;C blue#2 aluminum lake, and other ingredients.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First"><span class="Bold">Pharmacodynamics: </span>Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal, gastric, pancreatic, and intestinal glands and the mucous cells of the respiratory tract may be stimulated. When applied topically to the eye as a single dose it causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">spasm of accommodation</span>, and may cause a transitory rise in intraocular pressure followed by a more persistent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>. Dose-related smooth muscle stimulation of the intestinal tract may cause increased tone, increased motility, spasm, and tenesmus. Bronchial smooth muscle tone may increase. The tone and motility of urinary tract, gallbladder, and biliary duct smooth muscle may be enhanced. Pilocarpine may have paradoxical effects on the cardiovascular system. The expected effect of a muscarinic agonist is vasodepression, but administration of pilocarpine may produce <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> after a brief episode of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have both been reported with use of pilocarpine.</p>
<p>In a study of 12 healthy male volunteers there was a dose-related increase in unstimulated salivary flow following single 5 and 10 mg oral doses of SALAGEN® Tablets. This effect of pilocarpine on salivary flow was time-related with an onset at 20 minutes and a peak effect at 1 hour with a duration of 3 to 5 hours (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Pharmacokinetics</a></span> section).</p>
<p>Head &amp; Neck Cancer Patients: In a 12 week randomized, double-blind, placebo-controlled study in 207 patients (placebo, N=65; 5 mg, N=73; 10 mg, N=69), increases from baseline (means 0.072 and 0.112 mL/min, ranges -0.690 to 0.728 and -0.380 to 1.689) of whole saliva flow for the 5 mg (63%) and 10 mg (90%) tablet, respectively, were seen 1 hour after the first dose of SALAGEN® Tablets. Increases in unstimulated parotid flow were seen following the first dose (means 0.025 and 0.046 mL/min, ranges 0 to 0.414 and -0.070 to 1.002 mL/min for the 5 and 10 mg dose, respectively). In this study, no correlation existed between the amount of increase in salivary flow and the degree of symptomatic relief. </p>
<p>Sjogren's Syndrome Patients: In two 12 week randomized, double-blind, placebo-controlled studies in 629 patients (placebo, N=253; 2.5 mg, N=121; 5 mg, N=255; 5-7.5 mg, N=114), the ability of SALAGEN® Tablets to stimulate saliva production was assessed. In these trials using varying doses of SALAGEN® Tablets (2.5-7.5 mg), the rate of saliva production was plotted against time. An Area Under the Curve (AUC) representing the total amount of saliva produced during the observation interval was calculated. Relative to placebo, an increase in the amount of saliva being produced was observed following the first dose of SALAGEN® Tablets and was maintained throughout the duration (12 weeks) of the trials in an approximate dose response fashion (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Clinical Studies </a></span>section).</p>
<p><span class="Bold">Pharmacokinetics: </span>In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose. Tmax values were 1.25 hours and 0.85 hours. Cmax values were 15 ng/mL and 41 ng/mL. The AUC trapezoidal values were 33 h(ng/mL) and 108 h(ng/mL), respectively, for the 5 and 10 mg doses following the last 6 hour dose.</p>
<p>Pharmacokinetics in elderly male volunteers (N=11) were comparable to those in younger men. In five healthy elderly female volunteers, the mean Cmax and AUC were approximately twice that of elderly males and young normal male volunteers.</p>
<p>When taken with a high fat meal by 12 healthy male volunteers, there was a decrease in the rate of absorption of pilocarpine from SALAGEN® Tablets. Mean Tmax's were 1.47 and 0.87 hours, and mean Cmax's were 51.8 and 59.2 ng/mL for fed and fasted, respectively.</p>
<p>Limited information is available about the metabolism and elimination of pilocarpine in humans. Inactivation of pilocarpine is thought to occur at neuronal synapses and probably in plasma. Pilocarpine and its minimally active or inactive degradation products, including pilocarpic acid, are excreted in the urine. Pilocarpine does not bind to human or rat plasma proteins over a concentration range of 5 to 25,000 ng/mL. The effect of pilocarpine on plasma protein binding of other drugs has not been evaluated.</p>
<p>In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (N=12), administration of a single 5 mg dose resulted in a 30% decrease in total plasma clearance and a doubling of exposure (as measured by AUC). Peak plasma levels were also increased by about 30% and half-life was increased to 2.1 hrs. </p>
<p>There were no significant differences in the pharmacokinetics of oral pilocarpine in volunteer subjects (N=8) with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (mean creatinine clearances 25.4 mL/min; range 9.8 - 40.8 mL/min) compared to the pharmacokinetics previously observed in normal volunteers.</p>
<p><span class="Bold">Clinical Studies: </span>Head &amp; Neck Cancer Patients:</p>
<p>A 12 week randomized, double-blind, placebo-controlled study in 207 patients (142 men, 65 women) was conducted in patients whose mean age was 58.5 years with a range of 19 to 77; the racial distribution was Caucasian 95%, Black 4%, and other 1%. In this population, a statistically significant improvement in mouth dryness occurred in the 5 and 10 mg SALAGEN® Tablet treated patients compared to placebo treated patients. The 5 and 10 mg treated patients could not be distinguished. (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Pharmacodynamics</a></span> section for flow study details.)</p>
<p>Another 12 week, double-blind, randomized, placebo-controlled study was conducted in 162 patients whose mean age was 57.8 years with a range of 27 to 80; the racial distribution was Caucasian 88%, Black 10%, and other 2%. The effects of placebo were compared to 2.5 mg three times a day of SALAGEN® Tablets for 4 weeks followed by adjustment to 5 mg three times a day and 10 mg three times a day. Lowering of the dose was necessary because of adverse events in 3 of 67 patients treated with 5 mg of SALAGEN® Tablets and in 7 of 66 patients treated with 10 mg of SALAGEN® Tablets. After 4 weeks of treatment, 2.5 mg of SALAGEN® Tablets three times a day was comparable to placebo in relieving dryness. In patients treated with 5 mg and 10 mg of SALAGEN® Tablets, the greatest improvement in dryness was noted in patients with no measurable salivary flow at baseline.</p>
<p>In both studies, some patients noted improvement in the global assessment of their <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, speaking without liquids, and a reduced need for supplemental oral comfort agents.</p>
<p>In the two placebo-controlled clinical trials, the most common adverse events related to drug, and increasing in rate as dose increases, were <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. The most common adverse experience causing withdrawal from treatment was <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (<span class="Underline">5 mg t.i.d. ≤1%; 10 mg t.i.d. =12%</span>).</p>
<p>Sjogren's Syndrome Patients: Two separate studies were conducted in patients with primary or secondary Sjogren's Syndrome. In both studies, the majority of patients best fit the European criteria for having primary Sjogren's Syndrome. ["Criteria for the Classification of Sjogren's Syndrome" (Vitali C, Bombardieri S, Moutsopoulos HM, et al: Preliminary criteria for the classification of Sjogren's Syndrome. <span class="Italics"><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> Rheum</span>. 1993; 36:340-347.)]</p>
<p>A 12-week, randomized, double-blind, parallel-group, placebo-controlled study was conducted in 256 patients (14 men, 242 women) whose mean age was 57 years with a range of 24 to 85 years. The racial distribution was as follows: Caucasian 91%, Black 6%, and other 3%.</p>
<p>The effects of placebo were compared with those of SALAGEN® Tablets 5 mg four times a day (20 mg/day) for 6 weeks. At 6 weeks, the patients' dosage was increased from 5 mg SALAGEN® Tablets q.i.d. to 7.5 mg q.i.d. The data collected during the first 6 weeks of the trial were evaluated for safety and efficacy, and the data of the second 6 weeks of the trial were used to provide additional evidence of safety.</p>
<p>After 6 weeks of treatment, statistically significant global improvement of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> was observed compared to placebo. "Global improvement" is defined as a score of 55 mm or more on a 100 mm visual analogue scale in response to the question, "Please rate your present condition of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>) compared with your condition at the start of this study. Consider the changes to your <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and other symptoms related to your <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> that have occurred since you have taken this medication." Patients' assessments of specific <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> symptoms such as severity of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, mouth <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, ability to speak without water, ability to sleep without drinking water, ability to swallow food without drinking, and a decreased use of saliva substitutes were found to be consistent with the significant global improvement described.</p>
<p>Another 12 week randomized, double-blind, parallel-group, placebo-controlled study was conducted in 373 patients (16 men, 357 women) whose mean age was 55 years with a range of 21 to 84. The racial distribution was Caucasian 80%, Oriental 14%, Black 2%, and 4% of other origin. The treatment groups were 2.5 mg pilocarpine tablets, 5 mg SALAGEN® Tablets, and placebo. All treatments were administered on a four times a day regimen.</p>
<p>After 12 weeks of treatment, statistically significant global improvement of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> was observed at a dose of 5 mg compared with placebo. The 2.5 mg (10 mg/day) group was not significantly different than placebo. However, a subgroup of patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> tended to improve in global assessments at both the 2.5 mg q.i.d. (9 patients) and 5 mg q.i.d. (16 patients) dose (10-20 mg/day). The clinical significance of this finding is unknown.</p>
<p>Patients' assessments of specific <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> symptoms such as severity of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, mouth <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, ability to sleep without drinking water, and decreased use of saliva substitutes were also found to be consistent with the significant global improvement described when measured after 6 weeks and 12 weeks of SALAGEN® Tablets use.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">SALAGEN® Tablets are indicated for 1) the treatment of  symptoms of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> from salivary gland hypofunction  caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> in patients with Sjogren's Syndrome.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">SALAGEN® Tablets are contraindicated in patients with  uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pilocarpine, and when <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> is undesirable, e.g., in acute <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> and in narrow-angle (angle closure) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First"><span class="Bold">Cardiovascular Disease: </span>Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by pilocarpine. <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> has been reported as a complication of pilocarpine toxicity from high ocular doses given for acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pilocarpine should be administered with caution in and under close medical supervision of patients with significant cardiovascular disease.</p>
<p><span class="Bold">Ocular: </span>Ocular formulations of pilocarpine have been reported to cause visual blurring which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception. Caution should be advised while driving at night or performing hazardous activities in reduced lighting.</p>
<p><span class="Bold">Pulmonary Disease: </span>Pilocarpine has been reported to increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpine hydrochloride should be administered with caution to and under close medical supervision in patients with controlled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> requiring pharmacotherapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS
</h1>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-7"></a><p></p>
<h1>
General<br>
</h1>
<p class="First">Pilocarpine toxicity is characterized by an exaggeration of its parasympathomimetic effects. These may include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, gastrointestinal spasm, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>.</p>
<p>The dose-related cardiovascular pharmacologic effects of pilocarpine include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Pilocarpine should be administered with caution to patients with known or suspected <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> or <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>. Contractions of the gallbladder or biliary smooth muscle could precipitate complications including <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">cholangitis</span>, and biliary obstruction.</p>
<p>Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate <span class="product-label-link" type="condition" conceptid="201690" conceptname="Renal colic">renal colic</span> (or "ureteral reflux"), particularly in patients with <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>.</p>
<p>Cholinergic agonists may have dose-related central nervous system effects. This should be considered when treating patients with underlying cognitive or psychiatric disturbances.</p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: Based on decreased plasma clearance observed in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the starting dose in these patients should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child-Pugh score of 5-6) do not require dosage reductions. To date, pharmacokinetic studies in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10-15) have not been carried out. The use of pilocarpine in these patients is not recommended.
</p>
<table width="80%">
<caption><span>
Child-Pugh Scoring System for <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</span></caption>
<col align="left" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="center">
Clinical and Biochemical Measurements
</th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">
Points Scored for Increasing Abnormality
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center"></th>
<th class="Botrule Lrule Rrule" align="center">
1
</th>
<th class="Botrule Lrule Rrule" align="center">
2
</th>
<th class="Botrule Lrule Rrule" align="center">
3
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">
* According to grading of Trey C, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span> D, and Saunders S. Treatment of <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> by exchange blood transfusion. N Engl J Med. 1966; 274:473-481.
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> (grade)*
</td>
<td class="Botrule Lrule Rrule" align="center">
None
</td>
<td class="Botrule Lrule Rrule" align="center">
1 and 2
</td>
<td class="Botrule Lrule Rrule" align="center">
3 and 4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
Absent
</td>
<td class="Botrule Lrule Rrule" align="center">
Slight
</td>
<td class="Botrule Lrule Rrule" align="center">
Moderate
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Bilirubin (mg. per 100 ml.)
</td>
<td class="Botrule Lrule Rrule" align="center">
1-2
</td>
<td class="Botrule Lrule Rrule" align="center">
2-3
</td>
<td class="Botrule Lrule Rrule" align="center">
&gt;3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Albumin (g. per 100 ml.)
</td>
<td class="Botrule Lrule Rrule" align="center">
3-5
</td>
<td class="Botrule Lrule Rrule" align="center">
2.8-3.5
</td>
<td class="Botrule Lrule Rrule" align="center">
&lt;2.8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time (sec. Prolonged)
</td>
<td class="Botrule Lrule Rrule" align="center">
1-4
</td>
<td class="Botrule Lrule Rrule" align="center">
4-6
</td>
<td class="Botrule Lrule Rrule" align="center">
&gt;6
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
For <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">Primary Biliary Cirrhosis</span>:- Bilirubin (mg. per 100 ml.)
</td>
<td class="Botrule Lrule Rrule" align="center">
1-4
</td>
<td class="Botrule Lrule Rrule" align="center">
4-10
</td>
<td class="Botrule Lrule Rrule" align="center">
&gt;10
</td>
</tr>
</tbody>
</table>
<p>Reference: Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for <span class="product-label-link" type="condition" conceptid="28779" conceptname="Bleeding esophageal varices">bleeding oesophageal varices</span>. <span class="Italics">Brit J Surg. </span>1973; 60:646-9.
</p>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-7.1"></a><p></p>
<h2>
Information for Patients
</h2>
<p class="First">Patients should be informed that pilocarpine may cause  <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, especially at night, that could impair  their ability to drive safely.</p>
<p>If a patient sweats excessively while taking pilocarpine hydrochloride and cannot drink enough liquid, the patient should consult a physician. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> may develop.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-7.2"></a><p></p>
<h2>
Drug Interactions
</h2>
<p class="First">Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with pilocarpine would be expected to result in additive pharmacologic effects. Pilocarpine might antagonize the anticholinergic effects of drugs used concomitantly. These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).</p>
<p>While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprog-esterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-7.3"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Lifetime oral carcinogenicity studies were conducted in CD-1 mice and Sprague-Dawley rats. Pilocarpine did not induce tumors in mice at any dosage studied (up to 30 mg/kg/day, which yielded a systemic exposure approximately 50 times larger than the maximum systemic exposure observed clinically). In rats, a dosage of 18 mg/kg/day, which yielded a systemic exposure approximately 100 times larger than the maximum systemic exposure observed clinically, resulted in a statistically significant increase in the incidence of benign <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in both males and females, and a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> in female rats. The tumorigenicity observed in rats was observed only at a large multiple of the maximum labeled clinical dose, and may not be relevant to clinical use.</p>
<p>No evidence that pilocarpine has the potential to cause genetic toxicity was obtained in a series of studies that included: 1) bacterial assays (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>and <span class="Italics">E. coli </span>) for reverse gene mutations; 2) an <span class="Italics">in vitro </span>chromosome aberration assay in a Chinese hamster ovary cell line; 3) an <span class="Italics">in vivo </span>chromosome aberration assay (micronucleus test) in mice; and 4) a primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures.</p>
<p>Oral administration of pilocarpine to male and female rats at a dosage of 18 mg/kg/day, which yielded a systemic exposure approximately 100 times larger than the maximum systemic exposure observed clinically, resulted in impaired reproductive function, including reduced fertility, decreased sperm motility, and morphologic evidence of abnormal sperm. It is unclear whether the reduction in fertility was due to effects on male animals, female animals, or both males and females. In dogs, exposure to pilocarpine at a dosage of 3 mg/kg/day (approximately 3 times the maximum recommended human dose when compared on the basis of body surface area (mg/m2) estimates) for six months resulted in evidence of impaired spermatogenesis. The data obtained in these studies suggest that pilocarpine may impair the fertility of male and female humans. SALAGEN® Tablets should be administered to individuals who are attempting to conceive a child only if the potential benefit justifies potential impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-7.4"></a><p></p>
<h2>
Pregnancy: Teratogenic Effects<br>
</h2>
<p class="First"><span class="Bold">Pregnancy Category C: </span>Pilocarpine was associated with a reduction in the mean fetal body weight and an increase in the incidence of skeletal variations when given to pregnant rats at a dosage of 90 mg/kg/day (approximately 26 times the maximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m2) estimates). These effects may have been secondary to maternal toxicity. In another study, oral administration of pilocarpine to female rats during gestation and lactation at a dosage of 36 mg/kg/day (approximately 10 times the maximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m2) estimates) resulted in an increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>; decreased neonatal survival and reduced mean body weight of pups were observed at dosages of 18 mg/kg/day (approximately 5 times the maximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m2) estimates) and above. There are no adequate and well-controlled studies in pregnant women. SALAGEN® Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-7.5"></a><p></p>
<h2>
Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from SALAGEN® Tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-7.6"></a><p></p>
<h2>
Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-7.7"></a><p></p>
<h2>
Geriatric Use
</h2>
<p class="First">Head &amp; Neck Cancer Patients: In the placebo-controlled clinical trials (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Clinical Studies</a></span> section) the mean age of patients was approximately 58 years (range 19 to 80). Of these patients, 97/369 (61/217 receiving pilocarpine) were over the age of 65 years. In the healthy volunteer studies, 15/150 subjects were over the age of 65 years. In both study populations, the adverse events reported by those over 65 years and those 65 years and younger were comparable. Of the 15 elderly volunteers (5 women, 10 men), the 5 women had higher Cmax's and AUC's than the men. (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Pharmacokinetics</a></span> section.)</p>
<p>Sjogren's Syndrome Patients: In the placebo-controlled clinical trials (See <span class="Bold Underline"><a href="#splSectionClinicalPharmacology">Clinical Studies</a></span> section), the mean age of patients was approximately 55 years (range 21 to 85). The adverse events reported by those over 65 years and those 65 years and younger were comparable except for notable trends for <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (See <span class="Bold Underline"><a href="#splSectionAdverseReactions">ADVERSE REACTIONS</a></span> section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-8"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">Head &amp; Neck Cancer Patients: In controlled studies, 217 patients received pilocarpine, of whom 68% were men and 32% were women. Race distribution was 91% Caucasian, 8% Black, and 1% of other origin. Mean age was approximately 58 years. The majority of patients were between 50 and 64 years (51%), 33% were 65 years and older and 16% were younger than 50 years of age.</p>
<p>The most frequent adverse experiences associated with SALAGEN® Tablets were a consequence of the expected pharmacologic effects of pilocarpine.</p>
<table width="80%">
<col align="left" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">
Pilocarpine HCI
</th>
<th class="Botrule Lrule Rrule" align="center">
Placebo
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center">
10 mg t.i.d.<br>(30 mg/day)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 mg t.i.d.<br>(15 mg/day)
</td>
<td class="Botrule Lrule Rrule" align="center">
(t.i.d.)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
N=121/68%
</td>
<td class="Botrule Lrule Rrule" align="center">
N=141/ 29%
</td>
<td class="Botrule Lrule Rrule" align="center">
N=152/9%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
15
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
14
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
15
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
&lt;1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
13
</td>
<td class="Botrule Lrule Rrule" align="center">
8
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
12
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
12
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
12
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
</tr>
</tbody>
</table>
<p>In addition, the following adverse events (≥3% incidence) were reported at dosages of 15-30 mg/day in the controlled clinical trials: </p>
<table width="80%">
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center">
Pilocarpine HCI
</th>
<th class="Botrule Lrule Rrule" align="center">
Placebo
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center">
5-10 mg t.i.d.<br>(15-30 mg/day)
</td>
<td class="Botrule Lrule Rrule" align="center">
(t.i.d.)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
N=212/11%
</td>
<td class="Botrule Lrule Rrule" align="center">
N=152/8%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
8
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
1
</td>
</tr>
</tbody>
</table>
<p>The following events were reported with treated head and neck cancer patients at incidences of 1% to 2% at dosages of 7.5 to 30 mg/day: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span>.</p>
<p>The following events were reported rarely in treated head and neck cancer patients (&lt;1%):</p>
<p>Causal relation is unknown.</p>
<p>Body as a whole: <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">body odor</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, mucous membrane abnormality</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, ECG abnormality, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p>Digestive: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span></p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p>
<p>Nervous: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, parethesias, speech disorder, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span></p>
<p>Respiratory: increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span></p>
<p>Skin: <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span></p>
<p>Special senses: <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></p>
<p>Urogenital: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, urinary impairment</p>
<p>In long-term treatment were two patients with underlying cardiovascular disease of whom one experienced a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarct</span> and another an episode of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. The association with drug is uncertain.</p>
<p>Sjogren's Syndrome Patients: In controlled studies, 376 patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was 84% Caucasian, 9% Oriental, 3% Black, and 4% of other origin. Mean age was 55 years. The majority of patients were between 40 and 69 years (70%), 16% were 70 years and older and 14% were younger than 40 years of age. Of these patients, 161/629 (89/376 receiving pilocarpine) were over the age of 65 years. The adverse events reported by those over 65 years and those 65 years and younger were comparable except for notable trends for <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The incidences of <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the elderly were about double those of the non-elderly. The incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was about three times as high in the elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebo-controlled studies, the most common adverse events related to drug use were <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>). The most commonly reported reason for patient discontinuation of treatment was <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. Expected pharmacologic effects of pilocarpine include the following adverse experiences associated with SALAGEN® Tablets:
</p>
<table width="80%">
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center">
Pilocarpine HCI
</th>
<th class="Botrule Lrule Rrule" align="center">
Placebo
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center">
5 mg q.i.d.<br>(20 mg/day)
</td>
<td class="Botrule Lrule Rrule" align="center">
(q.i.d)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
N=255/40%
</td>
<td class="Botrule Lrule Rrule" align="center">
N=253/7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
<td class="Botrule Lrule Rrule" align="center">
8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased Salivation</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
</tr>
</tbody>
</table>
<p>In addition, the following adverse events (≥3% incidence) were reported at dosages of 20 mg/day in the controlled clinical trials:
</p>
<table width="80%">
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center">
Pilocarpine HCI
</th>
<th class="Botrule Lrule Rrule" align="center">
Placebo
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center">
5 mg q.i.d.<br>20 mg/day
</td>
<td class="Botrule Lrule Rrule" align="center">
(q.i.d)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
N=255/13%
</td>
<td class="Botrule Lrule Rrule" align="center">
N=253/19%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
<td class="Botrule Lrule Rrule" align="center">
9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
<td class="Botrule Lrule Rrule" align="center">
1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
3
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
</tr>
</tbody>
</table>
<p>The following events were reported in Sjogren's patients at incidences of 1% to 2% at dosing of 20 mg/day: <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, lab test abnor-malities, including chemistry, hematology, and urinalysis, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
<p>The following events were reported rarely in treated Sjogren's patients (&lt;1%) at dosing of 10-30 mg/day: Causal relation is unknown.</p>
<p>Body as a whole: <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> Cardiovascular: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, ECG abnormality, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p>
<p>Digestive: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, gas-trointestinal disorder, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4106572" conceptname="Hypertrophy of parotid gland">parotid gland enlargement</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland enlargement</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> increased, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span></p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">abnormal platelets</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, abnormal WBC</p>
<p>Metabolic and Nutritional: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorder</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">spontaneous bone fracture</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorder</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></p>
<p>Nervous: <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, parethesias, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p>Respiratory: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p>
<p>Skin: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span></p>
<p>Special Senses: <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorder</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorder</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder, <span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">retinal disorder</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span></p>
<p>Urogenital: <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4207977" conceptname="Disorder of ovary">ovarian disorder</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="4338958" conceptname="Salpingitis">salpingitis</span>, <span class="product-label-link" type="condition" conceptid="4280509" conceptname="Pain in urethra">urethral pain</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span></p>
<p>The following adverse experiences have been reported rarely with ocular pilocarpine: A-V block, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, ciliary congestion, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, middle ear disturbance, <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">eyelid twitching</span>, malignant <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4292727" conceptname="Cyst of iris">iris cysts</span>, <span class="product-label-link" type="condition" conceptid="4338894" conceptname="Macular hole">macular hole</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and visual <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-9"></a><p></p>
<h1>
MANAGEMENT OF <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>
</h1>
<p class="First">Fatal overdosage with pilocarpine has been reported in the scientific literature at doses presumed to be greater than 100 mg in two hospitalized patients. 100 mg of pilocarpine is considered potentially fatal. Overdosage should be treated with atropine titration (0.5 mg to 1.0 mg given subcutaneously or intravenously) and supportive measures to maintain respiration and circulation. Epinephrine (0.3 mg to 1.0 mg, subcutaneously or intramuscularly) may also be of value in the presence of severe cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>. It is not known if pilocarpine is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-10"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION:<br>
</h1>
<p class="First">Regardless of the indication, the starting dose in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> do not require dosage reductions. The use of pilocarpine in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> is not recommended. If needed, refer to the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> </span>subsection of the <span class="Bold">Precautions </span>section of this label for definitions of mild, moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Head &amp; Neck Cancer Patients: The recommended initial dose of SALAGEN® Tablets is 5 mg taken three times a day. Dosage should be titrated according to therapeutic response and tolerance. The usual dosage range is up to 15-30 mg per day. (Not to exceed 10 mg per dose.) Although early improvement may be realized, at least 12 weeks of uninterrupted therapy with SALAGEN® Tablets may be necessary to assess whether a beneficial response will be achieved. The incidence of the most common adverse events increases with dose. The lowest dose that is tolerated and effective should be used for maintenance.</p>
<p>Sjogren's Syndrome Patients: The recommended dose of SALAGEN® Tablets is 5 mg taken four times a day. Efficacy was established by 6 weeks of use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-11"></a><p></p>
<h1>
HOW SUPPLIED:<br>
</h1>
<p class="First">SALAGEN® Tablets, 5 mg, are white, film coated, debossed round tablets, coded SAL 5. Each tablet contains 5 mg pilocarpine hydrochloride. They are supplied as follows:</p>
<p>NDC 62856-705-10 bottles of 100</p>
<p>Store up to 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).</p>
<p>SALAGEN® Tablets, 7.5 mg, are blue, film coated, debossed round tablets, coded SAL 7.5. Each tablet contains 7.5 mg pilocarpine hydrochloride. They are supplied as follows:</p>
<p>NDC 62856-775-10 bottles of 100</p>
<p>Store up to 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).</p>
<p>Manufactured by:                                                                       201370</p>
<p>Patheon Inc.,</p>
<p>Ontario, L5N 7K9</p>
<p>Manufactured for:</p>
<p>Eisai Inc.</p>
<p>Woodcliff Lake, NJ 07677</p>
<p>© 2009 Eisai Inc. January 2009</p>
<p>SALAGEN® is a registered trademark of Eisai Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-12"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<div class="Figure"><img alt="
salagen-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb4810ec-d26f-429d-b87c-5898a7870169&amp;name=salagen-01.jpg"></div>
<p class="First"> </p>
<div class="Figure"><img alt="
salagen-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb4810ec-d26f-429d-b87c-5898a7870169&amp;name=salagen-02.jpg"></div>
<p> </p>
<div class="Figure"><img alt="
salagen-03
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb4810ec-d26f-429d-b87c-5898a7870169&amp;name=salagen-03.jpg"></div>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SALAGEN 		
					</strong><br><span class="contentTableReg">pilocarpine hyrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62856-705</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PILOCARPINE HYDROCHLORIDE</strong> (PILOCARPINE) </td>
<td class="formItem">PILOCARPINE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SAL;7;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62856-705-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:62856-705-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020237</td>
<td class="formItem">03/22/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SALAGEN 		
					</strong><br><span class="contentTableReg">pilocarpine hyrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62856-775</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PILOCARPINE HYDROCHLORIDE</strong> (PILOCARPINE) </td>
<td class="formItem">PILOCARPINE HYDROCHLORIDE</td>
<td class="formItem">7.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SAL;7;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62856-775-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020237</td>
<td class="formItem">03/22/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Eisai Inc.
							(831600833)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Eisai Inc. (831600833)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Eisai Inc.</td>
<td class="formItem"></td>
<td class="formItem">624009093</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fb4810ec-d26f-429d-b87c-5898a7870169</div>
<div>Set id: fb4810ec-d26f-429d-b87c-5898a7870169</div>
<div>Version: 1</div>
<div>Effective Time: 20091201</div>
</div>
</div> <div class="DistributorName">Eisai Inc.</div></p>
</body></html>
